10:30-11:45 a.m.
The William and Ida Friday Center for Continuing Education

10:30-10:35 a.m.
Session Host and Moderator: Ralph Baric, PhD
, Professor, Epidemiology, UNC Gillings School of Global Public Health; Professor, Microbiology and Immunology, School of Medicine; UNC-Chapel Hill

10:30-10:50 a.m.
“Unraveling Influenza Virus Pathogenic Mechanisms; from the Early Flu Hunters to Today”
Adolfo Garcia-Sastre, PhD
, Director, Global Health and Emerging Pathogens Institute; Professor, Microbiology; Fishberg Professor of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai

Dr. Adolfo Garcia-Sastre

Dr. Adolfo Garcia-Sastre

Adolfo Garcia-Sastre, PhD, has focused his research over the past 25 years on the molecular biology of influenza viruses and several other negative-strand RNA viruses. He has made major contributions to the influenza virus field, including the development of new genetics techniques and vaccine candidates against different infectious diseases, e.g., malaria and AIDS. His research has resulted in more than 480 scientific publications and reviews. Dr. Garcia-Sastre is Director of the Center for Research on Influenza Pathogenesis, one of the five Centers of Excellence for Influenza Research and Surveillance funded by the National Institute of Allergy and Infectious Diseases. His publication in Science on the reconstruction and characterization of the pandemic influenza virus of 1918 was awarded the paper of the year distinction by Lancet in 2005.

Selected publications:

  1. Grant A, Ponia S, Tripathi S, Balasubramaniam V, Miorin L, Sourisseau M, Schwarz M, Sánchez-Seco M, Evans M, Best S, García-Sastre A. Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host & Microbe 2016; 19: 882-890.
  2. Langlois R, Albrecht R, Kimble B, Sutton T, Shapiro J, Finch C, Angel M, Chua M, Gonzalez-Reiche A, Xu K, Perez D, García-Sastre A. MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. Nat. Biotech. 2013; 31: 844-847.
  3. Tumpey T, Basler C, Aguilar P, Zeng H, Solorzano A, Swayne D, Cox N, Katz J, Taubenberger J, Palese P, García-Sastre A. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 2005; 310: 77-80.

10:50-11:10 a.m.
“Developing Better Vaccines: Right Around the Corner?”
Barney S. Graham, MD, PhD
, Deputy Director, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID)

Dr. Barney Graham

Dr. Barney S. Graham

Barney S. Graham, MD, PhD, is an immunologist, virologist and clinical trials physician whose primary interests are viral pathogenesis, immunity and vaccine development. His work is focused on HIV, respiratory syncytial virus (RSV), influenza, coronaviruses and other emerging viral diseases. In 2000, he became one of the founding investigators for the NIAID Vaccine Research Center at the National Institutes of Health, where he is now the Deputy Director and Chief of the Viral Pathogenesis Laboratory and oversees the advanced development of candidate vaccine products. His laboratory investigates basic mechanisms by which T cells affect viral clearance and immunopathology, explores mechanisms of antibody-mediated viral neutralization, and develops vaccine approaches for respiratory virus infections and emerging viral diseases, including Zika and MERS coronavirus. He is a recipient of the Robert M. Chanock Award for lifetime contributions to RSV research. He serves as a consultant for organizations involved in vaccine development for HIV, tuberculosis, malaria, RSV and emerging viral pathogens.

Selected publications:

  1. Graham BS. Advances in antiviral vaccine development. (link is external) Immunol Rev. 2013 Sep;255(1):230-42.
  2. Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides JF, Sawatzki K, Hua A, Liu P, Tay MZ, Seaton KE, Shen X, Foulger A, Lloyd KE, Parks R, Pollara J, Ferrari G, Yu JS, Vandergrift N, Montefiori DC, Sobieszczyk ME, Hammer S, Karuna S, Gilbert P, Grove D, Grunenberg N, McElrath MJ, Mascola JR, Koup RA, Corey L, Nabel GJ, Morgan C, Churchyard G, Maenza J, Keefer M, Graham BS, Baden LR, Tomaras GD, Haynes BF. HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science. 2015 Aug 14;349(6249):aab1253. doi: 10.1126/science.aab1253. Epub 2015 Jul 30.
  3. Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kochar N, Wang J, Eshleman SH, Mayer KH, Magaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, Cohen M, Corey L. Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Stat Commun Infect Dis. 2017 Jan;9(1). pii: 20160001. doi: 10.1515/scid-2016-0001. Epub 2017 Jun 6.

11:15-11:35 a.m.
“Better Antivirals: Will They Be Ready?”
Frederick G. Hayden, MD
, Stuart S. Richardson Professor Emeritus of Clinical Virology; Professor Emeritus of Medicine, University of Virginia School of Medicine

Dr. Frederick Hayden

Dr. Frederick G. Hayden

Frederick G. Hayden, MD, focuses his research on respiratory viral infections, with a particular focus on the development and application of antiviral agents for influenza, rhinovirus and other respiratory viruses. He previously served as a Medical Officer in the Global Influenza Programme at the World Health Organization (WHO) and as Influenza Research Coordinator at the Wellcome Trust in London. He has published more than 350 peer-reviewed articles, chapters and reviews, and he co-edits, with Douglas Richman and Richard Whitley, the textbook Clinical Virology. In 2012-2013, he worked with WHO colleagues to develop the Battle against Respiratory Viruses (BRAVE) to foster research on this important public health problem. He also helped to establish the International Severe Acute Respiratory and Emerging Infection Consortium to improve the clinical research response to respiratory and other emerging infectious disease threats.

Selected publications:

  1. Hui DS, Hayden FG, Editorial commentary: host and viral factors in emergent influenza virus infections., 2014; Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 58(8) 1104-6. PMID: 24488976
  2. Bresee J, Hayden FG, Epidemic influenza–responding to the expected but unpredictable., 2013; The New England journal of medicine. 368(7) 589-92. PMID: 23343038
  3. McCullers JA, Hayden FG, Fatal influenza B infections: time to reexamine influenza research priorities., 2012; The Journal of infectious diseases. 205(6) 870-2. PMID: 22291194

11:35-11:50 a.m.
Moderated questions/discussion

11:50 a.m. – 12:40 p.m.
Lunch in the Trillium Room

Visit our communications and marketing team page.
Contact sphcomm@unc.edu with any media inquiries or general questions.

Communications and Marketing Office
125 Rosenau Hall
CB #7400
135 Dauer Drive
Chapel Hill, NC 27599-7400